Neurescue Revenue

About Neurescue

Neurescue develops cardiovascular devices to improve outcomes for emergency patients. Its flagship product, the NEURESCUE® device, an intelligent & fluoroscopy-free balloon catheter, is the first approved for the treatment of non-shockable cardiac arrest. By increasing blood flow to the brain and heart, the NEURESCUE device helps increase resuscitation rates. Every year, 81% of cardiac arrest patients present as non-shockable, making them ineligible for defibrillation. Today, only 4% of these patients survive. The NEURESCUE device directly addresses this urgent unmet need. The NEURESCUE device consists of a catheter and a handheld control unit. By temporarily inflating a soft balloon in the descending aorta, it redirects blood flow toward the heart and brain, supercharging circulation to the most critical organs during CPR. The intelligent, fluoroscopy-free device can boost central blood flow within one minute of deployment, thereby restoring the patient’s heartbeat in itself and buying time to bridge the patient to interventions such as a heart-lung-machine, percutaneous ventricular assist devices, and percutaneous coronary intervention. The device features automated inflation and sensor-guided feedback to facilitate a precise and safe procedure from start to finish. About Non-shockable Cardiac Arrest Non-shockable cardiac arrest cannot be treated with defibrillators. To survive a cardiac arrest, a patient must maintain blood flow to both the brain and the heart and achieve a return of spontaneous circulation (a regained heartbeat) or conversion to a shockable rhythm, either of which makes the patient eligible to be bridged to additional therapy.

View contact profiles from Neurescue